Company intelligence / Profile preview
OpenBiome
Cambridge, Massachusetts, United Statesopenbiome.org ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
OpenBiome has provided investigational fecal microbiota transplantation to over 65,000 patients with recurrent C. difficile infections and supported more than 40 clinical studies across a range of disease areas. The organization continues to develop new live biotherapeutic therapies targeting malnutrition and supports global research into the human microbiome’s role in health and disease.
- Therapeutic areas
- Metabolic DisordersImmunologyNeurologyInfectious Diseases
- Modalities
- Live biotherapeutics (fecal microbiota transplantation / FMT)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Collaborations with leading academic researchers globallyPartnerships with clinicians at hospitals treating rCDI
Beyond the preview
Go deeper on OpenBiome.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OpenBiome.